Contrasting Incretin-Based Therapies for the Treatment of Type 2 Diabetes
Einstein/Montefiore Department of Medicine Grand Rounds
Thursday, April 19, 2012
12:15 PM: Cherhasky Auditorium, Montefiore Medical Center
Speaker & Info
Daniel Drucker, MD
Professor of Medicine
Director, Banting and Best Diabetes Centre
University of Toronto
Dr. Daniel Drucker received his M.D. from the University of Toronto in 1980, and was appointed to the Division of Endocrinology, Department of Medicine, University of Toronto in 1987. He is currently Professor of Medicine and holds a Canada Research Chair in Regulatory Peptides and the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology. Dr. Drucker's laboratory is based in the Samuel Lunenfeld Research Institute at Mt. Sinai Hospital in Toronto and studies the molecular biology and physiology of the glucagon-like peptides with a focus on the potential therapeutic role of GLP-1, DPP-4 inhibitors and GLP-2 in the treatment of diabetes and intestinal diseases, respectively.
Objectives - After attending this activity, participants will be able to:
- Identify mechanisms of action of two principal incretin hormones
- Contrast differences between GIP and GLP-1 action
- Discriminate between glucoregulatory mechanisms underlying actions of GLP-1R agonists and DPP-4 inhibitors
- Enumerate cardiovascular actions of incretin-based therapies
- Review existing clinical trial data and ongoing cardiovascular safety trials for incretin-based therapies
Accreditation: Albert Einstein College of Medicine of Yeshiva University designates this live educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine of Yeshiva University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Department of Medicine